A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer

Pembrolizumab monotherapy or combination therapy is an approved treatment for various advanced non-small cell lung cancer (NSCLC) indications. We review published cost-effectiveness analyses (CEAs) of pembrolizumab as treatment for NSCLC and provide in-depth assessment of their methodologies. Fourte...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Nan, Insinga, Ralph, de Lima Lopes Junior, Gilberto, Cook, John, Sénécal, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333166/
https://www.ncbi.nlm.nih.gov/pubmed/33469803
http://dx.doi.org/10.1007/s41669-020-00255-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333166/
https://www.ncbi.nlm.nih.gov/pubmed/33469803
http://dx.doi.org/10.1007/s41669-020-00255-2

Ejemplares similares